Mast Therapeutics names Edwin Parsley as CMO

US-based clinical biopharmaceutical company Mast Therapeutics (NYSE MKT: MSTX) has named Edwin Parsley as its chief medical officer and senior vice president.

Dr Parsley has been actively engaged with the company since it acquired Aires Pharmaceuticals, in February 2014. He has served as Mast's interim chief medical officer since September 2014 and as chief medical officer of Aires since April 2011. Dr Parsley previously was with US pharma giant Pfizer (NYSE: PFE) where he oversaw clinical trials for Revatio (sildenafil). He is a practicing physician and certified by the American Board of Internal Medicine in internal medicine, pulmonary disease, critical care medicine, and sleep medicine.

Brian Culley, the company's chief executive officer, said: "Ed brings significant drug development and clinical expertise, as well as over 25 years of experience treating patients with a range of acute care needs, including patients with sickle cell disease, heart failure and stroke in emergency department and inpatient settings. Over the seven months since we acquired Aires, Ed has made valuable contributions to our programs and we are delighted he has joined our team. We believe his experience will help us achieve our clinical and preclinical development goals over the next 12 to 18 months.”